Dimesna

Drug Profile

Dimesna

Alternative Names: BNP 7787; Disodium 2,2'-dithio-bis ethane sulfonate; Tavocept

Latest Information Update: 22 Apr 2015

Price : $50

At a glance

  • Originator BioNumerik Pharmaceuticals
  • Class Alkanesulfonates; Chemoprotectants; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Glutaredoxin modulators; Thioredoxin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Peripheral nervous system diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lung cancer
  • No development reported Peripheral nervous system diseases

Most Recent Events

  • 22 Apr 2015 No recent reports of development identified - Phase-III for Lung cancer (Combination therapy) in Russia, Ukraine, Poland, Romania and Bulgaria (IV)
  • 22 Apr 2015 Phase III development is ongoing in the USA
  • 25 Jun 2013 No development reported - Phase-III for Peripheral nervous system diseases (Chemotherapy-induced, Prevention)/Chemoprotection in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top